不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
淋巴母细胞性非霍奇金淋巴瘤患儿的新冠病毒感染迁延不愈：最佳管理方案是什么？
英文原题：Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management?
查看英文原题
Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在2019冠状病毒病(COVID-19)大流行期间，肿瘤科医生管理的患者具有较高的重症感染风险。这引发了关于其正确管理的新问题，以及区分肿瘤/治疗并发症与COVID-19相关并发症的困难。我们报告一例正在接受T细胞淋巴母细胞淋巴瘤治疗的11岁男孩，其经历了延长的COVID-19病程。肿瘤治疗按原计划继续进行，未出现显著改变。未发生相关并发症。给予COVID-19恢复期血浆后，24天后抗体滴度呈阳性。
展开英文摘要原文
During the coronavirus disease 2019 (COVID-19) pandemic, oncologists have managed patients at higher risk of having a severe course of this infection. This raises new questions about their correct management, as well as the difficulty of distinguishing tumor/treatments complications from those related to COVID-19.
We report a case of an 11-year-old boy undergoing treatment for T-cell lymphoblastic lymphoma who experienced a prolonged COVID-19 course. Oncologic therapy was continued without significant changes compared to the initially planned treatment. No relevant complications occurred. COVID-19 convalescent plasma was administered, resulting in a positive antibody titer after 24 days.
论文信息
- 作者
- Gattuso G、Schiavello E、Oltolini C、Biassoni V、Terenziani M、Chiaravalli S、Podda MG、Meazza C
- 单位
- Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.Italy
- 文献类型
- 病例报告
- 期刊
- Tumori2022 Dec
- 原文标识
- PubMed 34965799 · DOI 10.1177/03008916211067825
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →